Skip to main content

Cookies on UKHSA data dashboard

We use some essential cookies to make this service work.

We'd like to set additional cookies so we can remember your settings, understand how people use the service and make improvements.

View cookies
UKHSA data dashboard

BetaThis is a new service - your feedback will help us to improve it.

Information
Amber cold health alert issued for North East and West, and Yorkshire and the Humber. Yellow cold alert issued the rest of England.

The amber alert affects North East, North West and Yorkshire and the Humber. The yellow alert affects the rest of England. Both alerts are in place from 12pm Mon 17 Nov until 8am Sat 22 Nov. Please see the Weather health alerts page.

Entry title:

Hepatitis B (HBV)

Last updated on Thursday, 20 November 2025 at 04:00pm

Hepatitis B virus (HBV) is a bloodborne virus (BBV) that infects the liver. Exposure to the hepatitis B virus causes an acute infection, a chronic infection occurs if the virus persists for greater than 6 months and over time can cause severe liver damage leading to cirrhosis, liver failure and cancer. Hepatitis B is vaccine preventable and has been part of the childhood immunisation programme since 2017. Vaccination is also recommended for individuals of all ages at increased risk of exposure to HBV or complications of the disease. These recommendations are outlined in the Green Book.

Through the surveillance of acute and chronic viral hepatitis, UKHSA monitors disease trends, identify populations disproportionately affected and inequities in access and outcomes of care. Data reported by local (NHS or private) or reference laboratories on testing for viral hepatitis is the primary source of surveillance data.

In 2016, the UK signed up to the WHO global health sector strategy (GHSS) to eliminate viral hepatitis as a public health threat by 2030. To validate elimination of viral hepatitis, it is necessary to demonstrate the achievement of the WHO impact and programmatic targets. The impact targets include absolute thresholds for incidence and mortality, and programmatic targets focus on diagnosis, treatment and prevention.

The impact targets are:

  • A mother to child transmission rate of less than 2%.
  • Less than 0.1% hepatitis B surface antigen (HBsAg) prevalence in children 5 years and under.
  • A combined annual mortality of 6 per 100,000 deaths or fewer attributable to hepatitis B or C

The programmatic targets are:

  • At least 90% coverage of 3 doses of HepB containing vaccines by 12 months of age.
  • At least 90% coverage of at-risk infants with targeted timely hepatitis B birth dose (HepB-BD).
  • At least 90% coverage of antenatal HBsAg screening.
  • At least 90% coverage with antivirals for eligible pregnant women.
  • 100% of healthcare facilities with safe injections or 90% of healthcare injection devices procured to be safety-engineered
  • 100% of blood donations to be screened
  • At least 90% of people living with chronic hepatitis B to be diagnosed.
  • At least 80% of people who are diagnosed with hepatitis B and eligible to be treated are treated.

We summarise England’s progress towards the WHO elimination targets for hepatitis B virus here and within the Hepatitis B in England Report. These metrics are updated annually. We will next update the data in November 2026.

Headlines

HBV prevalence estimates 2015 to 2021

Up to 31 Dec 2021
268,767

Mother to child transmission rate (where countries use a targeted birth dose programme. WHO Target: 90% or above)

Up to 31 Dec 2021
0.1

Coverage of those infants at risk with targeted timely hepatitis B birth dose (WHO Target: 90% or above)

Up to 31 Dec 2021
98

Coverage of maternal antenatal HBsAg testing (WHO Target: 90% or above)

Up to 31 Dec 2021
99.8

Hepatitis B mortality (WHO Target: 4 per 100,000 or less)

Up to 31 Dec 2021
0.3

Vaccinations

Coverage for universal hexavalent vaccine

England has consistently exceeded the WHO 90% coverage target for children receiving 3 doses of the hexavalent vaccine by their first birthday. The COVER annual report for 2024 to 2025 reported a slight increase in universal hexavalent vaccine coverage, with 91.3% of children being vaccinated by their first birthday compared to 91.2% in 2023 to 2024. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 Dec 2024

ChartThere are 2 plots on this chart. The horizontal X-axis is labelled 'date'. Whilst the vertical Y-axis is labelled 'metric'. This is plot number 1 on this chart. This is a dark blue solid line plot. The plot has a label of 'Hexavalent vaccine'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_vaccinations_coverageOf3Doses' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2019 to 31 December 2024. The date fluctuates between 92.6 on 31 December 2019, ending with the same value on 31 December 2019. The date fluctuates between 92.0 on 31 December 2020, ending with the same value on 31 December 2020. The date fluctuates between 91.8 on 31 December 2021, ending with the same value on 31 December 2021. The date fluctuates between 91.8 on 31 December 2022, ending with the same value on 31 December 2022. The date fluctuates between 91.2 on 31 December 2023, ending with the same value on 31 December 2023. And finally. The date fluctuates between 91.3 on 31 December 2024, ending with the same value on 31 December 2024. This is plot number 2 on this chart. This is a turquoise dash line plot. The plot has a label of 'WHO target'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_vaccinations_coverageOf3DosesTargetWHO' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2019 to 31 December 2024. The date fluctuates between 90.0 on 31 December 2019, ending with the same value on 31 December 2019. The date fluctuates between 90.0 on 31 December 2020, ending with the same value on 31 December 2020. The date fluctuates between 90.0 on 31 December 2021, ending with the same value on 31 December 2021. The date fluctuates between 90.0 on 31 December 2022, ending with the same value on 31 December 2022. The date fluctuates between 90.0 on 31 December 2023, ending with the same value on 31 December 2023. And finally. The date fluctuates between 90.0 on 31 December 2024, ending with the same value on 31 December 2024. There is no reporting delay period being tracked for the data on this chart. - Refer to tabular data.
Tabular data

Coverage for universal hexavalent vaccine data for england has consistently exceeded the WHO 90% coverage target for children receiving 3 doses of the hexavalent vaccine by their first birthday. The COVER annual report for 2024 to 2025 reported a slight increase in universal hexavalent vaccine coverage, with 91.3% of children being vaccinated by their first birthday compared to 91.2% in 2023 to 2024. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 December 2024

YearHexavalent vaccineWHO target
31 Dec 202491.3090.00
31 Dec 202391.2090.00
31 Dec 202291.8090.00
31 Dec 202191.8090.00
31 Dec 202092.0090.00
31 Dec 201992.6090.00
Download

Download data

Select format
About

Selective neonatal programme

Coverage of hepatitis B vaccination in the selective neonatal programme in England has increased over the past 6 years. The selective neonatal programme includes 5 hepatitis B vaccines (birth dose, monovalent dose at 4 weeks, and 3 hexavalent doses as part of the routine childhood immunisation schedule) by 12 months of age and a further monovalent dose at 12 months meaning that eligible infants should have all 6 doses by 24 months of age. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 Dec 2024

ChartThere are 2 plots on this chart. The horizontal X-axis is labelled 'date'. Whilst the vertical Y-axis is labelled 'metric'. This is plot number 1 on this chart. This is a blue solid line plot. The plot has a label of 'Percentage vaccinated with 5 doses by 12 months old'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_vaccinations_coverageSelectiveNeonatal12monthsOld' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2019 to 31 December 2024. The date fluctuates between 83.9 on 31 December 2019, ending with the same value on 31 December 2019. The date fluctuates between 85.4 on 31 December 2020, ending with the same value on 31 December 2020. The date fluctuates between 88.5 on 31 December 2021, ending with the same value on 31 December 2021. The date fluctuates between 90.1 on 31 December 2022, ending with the same value on 31 December 2022. The date fluctuates between 91.0 on 31 December 2023, ending with the same value on 31 December 2023. And finally. The date fluctuates between 93.6 on 31 December 2024, ending with the same value on 31 December 2024. This is plot number 2 on this chart. This is a dark blue solid line plot. The plot has a label of 'Percentage vaccinated with 6 doses by 24 months old'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_vaccinations_coverageSelectiveNeonatal24monthsOld' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2019 to 31 December 2024. The date fluctuates between 72.8 on 31 December 2019, ending with the same value on 31 December 2019. The date fluctuates between 77.7 on 31 December 2020, ending with the same value on 31 December 2020. The date fluctuates between 80.8 on 31 December 2021, ending with the same value on 31 December 2021. The date fluctuates between 83.0 on 31 December 2022, ending with the same value on 31 December 2022. The date fluctuates between 88.0 on 31 December 2023, ending with the same value on 31 December 2023. And finally. The date fluctuates between 89.3 on 31 December 2024, ending with the same value on 31 December 2024. There is no reporting delay period being tracked for the data on this chart. - Refer to tabular data.
Tabular data

Selective neonatal programme data for coverage of hepatitis B vaccination in the selective neonatal programme in England has increased over the past 6 years. The selective neonatal programme includes 5 hepatitis B vaccines (birth dose, monovalent dose at 4 weeks, and 3 hexavalent doses as part of the routine childhood immunisation schedule) by 12 months of age and a further monovalent dose at 12 months meaning that eligible infants should have all 6 doses by 24 months of age. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 December 2024

YearPercentage vaccinated with 5 doses by 12 months oldPercentage vaccinated with 6 doses by 24 months old
31 Dec 202493.6089.30
31 Dec 202391.0088.00
31 Dec 202290.1083.00
31 Dec 202188.5080.80
31 Dec 202085.4077.70
31 Dec 201983.9072.80
Download

Download data

Select format
About

Source: Childhood vaccination coverage statistics, NHS Digital (co-authored with UKHSA). Note 5: data prior to 2019 to 2020 is missing for some local authorities, particularly in London, and so is not presented. In July 2025 an additional hepatitis B hexavalent vaccine dose at 18 months of age was introduced to the universal schedule for babies reaching 12 months old on or after 1 July 2025; the monovalent vaccine dose at 12-months of age has therefore been removed from the selective schedule for these infants. The data presented here predates this change.

Coverage for timely hepatitis B birth dose vaccination

Whilst coverage of the hepatitis B birth dose vaccine within 24 hours of birth has remained high, and well over WHO targets (90% and above), there has been a small decline in recent years from 99.2% (1,834 out of 1,849) in 2020 to 2021 to 98.0% (1,786 out of 1,822) in 2023 to 2024. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 Dec 2023

ChartThere are 2 plots on this chart. The horizontal X-axis is labelled 'date'. Whilst the vertical Y-axis is labelled 'metric'. This is plot number 1 on this chart. This is a dark blue solid line plot. The plot has a label of 'Proportion of infants with timely hepatitis birth dose'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_vaccinations_percentageInfantsBirthDose' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2017 to 31 December 2023. The date fluctuates between 98.9 on 31 December 2017, ending with the same value on 31 December 2018. The date fluctuates between 98.5 on 31 December 2019, ending with the same value on 31 December 2019. The date fluctuates between 99.2 on 31 December 2020, ending with the same value on 31 December 2020. The date fluctuates between 98.8 on 31 December 2021, ending with the same value on 31 December 2021. The date fluctuates between 98.1 on 31 December 2022, ending with the same value on 31 December 2022. And finally. The date fluctuates between 98.0 on 31 December 2023, ending with the same value on 31 December 2023. This is plot number 2 on this chart. This is a turquoise dash line plot. The plot has a label of 'WHO target'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_vaccinations_percentageInfantsBirthDoseTargetWHO' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2017 to 31 December 2023. The date fluctuates between 90.0 on 31 December 2017, ending with the same value on 31 December 2018. The date fluctuates between 90.0 on 31 December 2019, ending with the same value on 31 December 2019. The date fluctuates between 90.0 on 31 December 2020, ending with the same value on 31 December 2020. The date fluctuates between 90.0 on 31 December 2021, ending with the same value on 31 December 2021. The date fluctuates between 90.0 on 31 December 2022, ending with the same value on 31 December 2022. And finally. The date fluctuates between 90.0 on 31 December 2023, ending with the same value on 31 December 2023. There is no reporting delay period being tracked for the data on this chart. - Refer to tabular data.
Tabular data

Coverage for timely hepatitis B birth dose vaccination data for whilst coverage of the hepatitis B birth dose vaccine within 24 hours of birth has remained high, and well over WHO targets (90% and above), there has been a small decline in recent years from 99.2% (1,834 out of 1,849) in 2020 to 2021 to 98.0% (1,786 out of 1,822) in 2023 to 2024. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 December 2023

YearProportion of infants with timely hepatitis birth doseWHO target
31 Dec 202398.0090.00
31 Dec 202298.1090.00
31 Dec 202198.8090.00
31 Dec 202099.2090.00
31 Dec 201998.5090.00
31 Dec 201898.9090.00
31 Dec 201798.9090.00
Download

Download data

Select format
About

Source: NHSE.

Related Links

Testing

Mother to child transmission rate

The estimated mother to child transmission rate has consistently been below the 2% WHO target, falling from 0.95% between April 2014 and March 2015 to 0.06% between April 2024 to March 2025. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 Dec 2024

ChartThere are 2 plots on this chart. The horizontal X-axis is labelled 'date'. Whilst the vertical Y-axis is labelled 'metric'. This is plot number 1 on this chart. This is a dark blue solid line plot. The plot has a label of 'Proportion positive'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_testing_motherToChildTransmissionRate' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2014 to 31 December 2024. It fell from 0.95 on 31 December 2014 to 0.32 on 31 December 2015. It rose from 0.11 on 31 December 2016 to 0.26 on 31 December 2017. The date fluctuates between 0.08 on 31 December 2018, ending with the same value on 31 December 2019. It fell from 0.24 on 31 December 2020 to 0.07 on 31 December 2021. It fell from 0.06 on 31 December 2022 to 0.0 on 31 December 2023. And finally. The date fluctuates between 0.06 on 31 December 2024, ending with the same value on 31 December 2024. This is plot number 2 on this chart. This is a turquoise dash line plot. The plot has a label of 'WHO target'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_testing_motherToChildTransmissionRateTargetWHO' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2014 to 31 December 2024. The date fluctuates between 2.0 on 31 December 2014, ending with the same value on 31 December 2015. The date fluctuates between 2.0 on 31 December 2016, ending with the same value on 31 December 2017. The date fluctuates between 2.0 on 31 December 2018, ending with the same value on 31 December 2019. The date fluctuates between 2.0 on 31 December 2020, ending with the same value on 31 December 2021. The date fluctuates between 2.0 on 31 December 2022, ending with the same value on 31 December 2023. And finally. The date fluctuates between 2.0 on 31 December 2024, ending with the same value on 31 December 2024. There is no reporting delay period being tracked for the data on this chart. - Refer to tabular data.
Tabular data

Mother to child transmission rate data for the estimated mother to child transmission rate has consistently been below the 2% WHO target, falling from 0.95% between April 2014 and March 2015 to 0.06% between April 2024 to March 2025. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 December 2024

YearProportion positiveWHO target
31 Dec 20240.062.00
31 Dec 20230.002.00
31 Dec 20220.062.00
31 Dec 20210.072.00
31 Dec 20200.242.00
31 Dec 20190.082.00
31 Dec 20180.082.00
31 Dec 20170.262.00
31 Dec 20160.112.00
31 Dec 20150.322.00
31 Dec 20140.952.00
Download

Download data

Select format
About

Maternal screening coverage

Antenatal screening uptake has consistently been above 99% between 2017 to 2024 exceeding the WHO target of 90%, ensuring that pregnant women living with hepatitis B are diagnosed and interventions are implemented to prevent transmission of hepatitis B to their children. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 Dec 2023

ChartThere are 2 plots on this chart. The horizontal X-axis is labelled 'date'. Whilst the vertical Y-axis is labelled 'metric'. This is plot number 1 on this chart. This is a dark blue solid line plot. The plot has a label of 'Hepatitis B screening coverage'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_testing_coverageOfMaternalAntenatalTesting' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2017 to 31 December 2023. It rose from 99.5 on 31 December 2017 to 99.7 on 31 December 2018. The date fluctuates between 99.8 on 31 December 2019, ending with the same value on 31 December 2019. The date fluctuates between 99.8 on 31 December 2020, ending with the same value on 31 December 2020. The date fluctuates between 99.8 on 31 December 2021, ending with the same value on 31 December 2021. The date fluctuates between 99.8 on 31 December 2022, ending with the same value on 31 December 2022. And finally. The date fluctuates between 99.8 on 31 December 2023, ending with the same value on 31 December 2023. This is plot number 2 on this chart. This is a turquoise dash line plot. The plot has a label of 'WHO target'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_testing_coverageOfMaternalAntenatalTestingTargetWHO' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2017 to 31 December 2023. The date fluctuates between 90.0 on 31 December 2017, ending with the same value on 31 December 2018. The date fluctuates between 90.0 on 31 December 2019, ending with the same value on 31 December 2019. The date fluctuates between 90.0 on 31 December 2020, ending with the same value on 31 December 2020. The date fluctuates between 90.0 on 31 December 2021, ending with the same value on 31 December 2021. The date fluctuates between 90.0 on 31 December 2022, ending with the same value on 31 December 2022. And finally. The date fluctuates between 90.0 on 31 December 2023, ending with the same value on 31 December 2023. There is no reporting delay period being tracked for the data on this chart. - Refer to tabular data.
Tabular data

Maternal screening coverage data for antenatal screening uptake has consistently been above 99% between 2017 to 2024 exceeding the WHO target of 90%, ensuring that pregnant women living with hepatitis B are diagnosed and interventions are implemented to prevent transmission of hepatitis B to their children. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 December 2023

YearHepatitis B screening coverageWHO target
31 Dec 202399.8090.00
31 Dec 202299.8090.00
31 Dec 202199.8090.00
31 Dec 202099.8090.00
31 Dec 201999.8090.00
31 Dec 201899.7090.00
31 Dec 201799.5090.00
Download

Download data

Select format
About

Source: IDPS programme standards reports and KPI indicator reports, NHSE.

Mortality

Mortality rate per 100,000 population

Deaths from hepatitis B-related ESLD and/or HCC have remained below 0.36 per 100,000 population since 2005 using the upper bound estimate. In 2024, the estimated annual hepatitis B-related ESLD and/or HCC mortality rate was between 0.18 (lower bound) and 0.35 (upper bound) per 100,000 population, and this rate has remained stable with upper estimates between 0.15 and 0.36 since 2005. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 Dec 2024

ChartThere are 2 plots on this chart. The horizontal X-axis is labelled 'date'. Whilst the vertical Y-axis is labelled 'metric'. This is plot number 1 on this chart. This is a dark blue solid line plot. The plot has a label of 'Rate for hepatitis B-related ESLD and/or HCC'. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_deaths_deathRateByYear' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2006 to 31 December 2024. It rose from 0.17 on 31 December 2006 to 0.18 on 31 December 2009. It fell from 0.18 on 31 December 2010 to 0.17 on 31 December 2012. It rose from 0.14 on 31 December 2013 to 0.16 on 31 December 2015. It rose from 0.14 on 31 December 2016 to 0.15 on 31 December 2018. The date fluctuates between 0.15 on 31 December 2019, ending with the same value on 31 December 2021. And finally. It rose from 0.15 on 31 December 2022 to 0.18 on 31 December 2024. This is plot number 2 on this chart. This is a turquoise dash line plot. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_deaths_deathRatebyYearTargetWHO' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 2006 to 31 December 2024. The date fluctuates between 4.0 on 31 December 2006, ending with the same value on 31 December 2009. The date fluctuates between 4.0 on 31 December 2010, ending with the same value on 31 December 2012. The date fluctuates between 4.0 on 31 December 2013, ending with the same value on 31 December 2015. The date fluctuates between 4.0 on 31 December 2016, ending with the same value on 31 December 2018. The date fluctuates between 4.0 on 31 December 2019, ending with the same value on 31 December 2021. And finally. The date fluctuates between 4.0 on 31 December 2022, ending with the same value on 31 December 2024. There is no reporting delay period being tracked for the data on this chart. - Refer to tabular data.
Tabular data

Mortality rate per 100,000 population data for deaths from hepatitis B-related ESLD and/or HCC have remained below 0.36 per 100,000 population since 2005 using the upper bound estimate. In 2024, the estimated annual hepatitis B-related ESLD and/or HCC mortality rate was between 0.18 (lower bound) and 0.35 (upper bound) per 100,000 population, and this rate has remained stable with upper estimates between 0.15 and 0.36 since 2005. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 December 2024

YearRate for hepatitis B-related ESLD and/or HCCAmount
31 Dec 20240.184.00
31 Dec 20230.174.00
31 Dec 20220.154.00
31 Dec 20210.154.00
31 Dec 20200.174.00
31 Dec 20190.154.00
31 Dec 20180.154.00
31 Dec 20170.144.00
31 Dec 20160.144.00
31 Dec 20150.164.00
31 Dec 20140.124.00
31 Dec 20130.144.00
31 Dec 20120.174.00
31 Dec 20110.194.00
31 Dec 20100.184.00
31 Dec 20090.184.00
31 Dec 20080.174.00
31 Dec 20070.184.00
31 Dec 20060.174.00
Download

Download data

Select format
About

Note 15: lower bound represents deaths where ESLD and/or HCC and hepatitis B were reported in ONS death registrations (as year of death is now used this is not comparable with previously published estimates which used year the death was registered). Upper bound represents deaths where ESLD and/or HCC were reported in ONS death registrations and hepatitis B diagnoses were identified by linking between ONS deaths, HES hospital admissions data and laboratory diagnosis data to yield a maximum number of deaths attributable to hepatitis B related ESLD and/or HCC.  Note 16: excluding deaths of people aged under 16 and deaths registered in England where the deceased’s usual residence is outside England.   Note 17: defined by codes or text entries for ascites, bleeding oesophageal varices, hepato-renal syndrome, hepatic encephalopathy, or hepatic failure.

Cases

Number of people diagnosed with acute hepatitis B

Between 2015 and 2024 an average of 332 acute hepatitis B diagnoses were reported annually to UKHSA (range from 175 to 457). Despite a continuous decline in the number of people with an acute hepatitis B infection in England since 2015, 277 individuals were reported in 2024 which indicates that reporting is returning to pre-pandemic levels. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 Dec 2024

ChartThere is only 1 plot on this chart. The horizontal X-axis is labelled 'date'. Whilst the vertical Y-axis is labelled 'metric'. This is a dark blue solid line plot. This plot shows data for Hepatitis-B. Specifically the metric 'hepatitis-b_cases_acuteIncidenceByYear' for the England area, along with the age banding of 'all' for the gender group of all. This plot shows data from 31 December 1980 to 31 December 2024. It rose from 1007.0 on 31 December 1980 to 1309.0 on 31 December 1986. It fell from 784.0 on 31 December 1987 to 629.0 on 31 December 1993. It rose from 633.0 on 31 December 1994 to 729.0 on 31 December 2000. It fell from 608.0 on 31 December 2001 to 589.0 on 31 December 2011. It fell from 554.0 on 31 December 2012 to 381.0 on 31 December 2018. And finally. It fell from 333.0 on 31 December 2019 to 277.0 on 31 December 2024. There is no reporting delay period being tracked for the data on this chart. - Refer to tabular data.
Tabular data

Number of people diagnosed with acute hepatitis B data for between 2015 and 2024 an average of 332 acute hepatitis B diagnoses were reported annually to UKHSA (range from 175 to 457). Despite a continuous decline in the number of people with an acute hepatitis B infection in England since 2015, 277 individuals were reported in 2024 which indicates that reporting is returning to pre-pandemic levels. Figures are annual, but shown as at December of each year. For example, the figures for 2022 are shown as at "Dec 2022".

Up to and including 31 December 2024

Calendar yearAmount
31 Dec 2024277.00
31 Dec 2023303.00
31 Dec 2022239.00
31 Dec 2021175.00
31 Dec 2020253.00
31 Dec 2019333.00
31 Dec 2018381.00
31 Dec 2017445.00
31 Dec 2016453.00
31 Dec 2015457.00
31 Dec 2014488.00
31 Dec 2013414.00
31 Dec 2012554.00
31 Dec 2011589.00
31 Dec 2010512.00
31 Dec 2009597.00
31 Dec 2008620.00
31 Dec 2003695.00
31 Dec 2002892.00
31 Dec 2001608.00
31 Dec 2000729.00
31 Dec 1999752.00
31 Dec 1998843.00
31 Dec 1997652.00
31 Dec 1996570.00
31 Dec 1995612.00
31 Dec 1994633.00
31 Dec 1993629.00
31 Dec 1992531.00
31 Dec 1991572.00
31 Dec 1990618.00
31 Dec 1989583.00
31 Dec 1988641.00
31 Dec 1987784.00
31 Dec 19861,309.00
31 Dec 19851,761.00
31 Dec 19841,937.00
31 Dec 19831,274.00
31 Dec 19821,237.00
31 Dec 19811,197.00
31 Dec 19801,007.00
Download

Download data

Select format
About

Note 12: data from 2004 to 2008 is not available due to change in the reporting and surveillance system. Laboratory and clinical reporting systems were reinstated in 2008. Note 13: UKHSA transitioned to a new case management system for notifiable diseases in 2024 which has impacted the identification of people with acute hepatitis B and likely resulted in underreporting.

Related content

Learn more about UKHSA data dashboard topics

Back to top